The purpose of this clinical trial is to administer a sodium pyruvate nasal spray that eliminates nasal oxidative stresses, caused by oxygen radicals, and demonstrate the efficacy of sodium pyruvate to reduce coughing and increase lung functions in patients with idiopathic pulmonary fibrosis. This will be a 21-day double-blinded randomized placebo-controlled trial designed to determine if patients with idiopathic pulmonary fibrosis treated with 20mM sodium pyruvate in 0.9% sodium chloride nasal spray solution will have reduced chronic coughing, as well as increased lung function (FEV1, FVC endpoints of 12% or more within the first week) and improved FEV1/FVC ratios.

Start Date15 Aug 2023

Sponsor / Collaborator

Mikra, Cellular Sciences, Inc.Startup

[+1]

KCT0007571 / RecruitingPhase 2IIT

A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-Groups, Dose Finding Exploratory Study to Evaluate Safety and Efficacy of BTS granule in Major Depressive Disorder

Start Date29 Sep 2022

Sponsor / Collaborator

Korea Institute of Oriental Medicine

CTR20220404 / CompletedPhase 2

评价丙酮酸钠吸入剂治疗稳定期慢性阻塞性肺疾病（COPD）的疗效和安全性的随机、双盲、安慰剂平行对照多中心Ⅱ期临床研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical study to evaluate the efficacy and safety of sodium pyruvate inhalation in the treatment of stable chronic obstructive pulmonary disease (COPD)

本研究的主要目的是以安慰剂为对照，在加载噻托溴铵粉吸入剂（思力华）的基础上探索不同剂量丙酮酸钠吸入剂连续给药 6 周对稳定期 COPD 受试者的有效性和安全性及剂量效应关系。

[Translation]

The main purpose of this study is to explore the efficacy, safety and dose-effect relationship of different doses of sodium pyruvate inhalation for 6 weeks in subjects with stable COPD, based on tiotropium bromide powder inhalation (Spiriva) as a placebo control.

Start Date28 Mar 2022

Sponsor / Collaborator

Pharmamax Pharmaceuticals Ltd.

100 Clinical Results associated with Sodium Pyruvate

100 Translational Medicine associated with Sodium Pyruvate

100 Patents (Medical) associated with Sodium Pyruvate

867

Literatures (Medical) associated with Sodium Pyruvate

01 Jan 2025·Biomaterials Advances

Enzyme-delivery Metal-organic Framework Composite Coatings for Restoration of Hyperglycemia-damaged Osteoblast Differentiation

Article

Author: Tilton, Maryam ; Elder, Benjamin D. ; Elder, Benjamin D ; Shafi, Mahnoor ; Potes, Maria Astudillo ; Lu, Lichun ; Mitra, Indranath

There is a significant clinical need to develop effective treatments for bone defects in patients with diabetes mellitus (DM), as they are at higher risk of fractures and impaired healing. Guided bone tissue engineering using biocompatible and biodegradable polymers is a promising approach. However, current diabetic bone regenerative therapies often fail due to the accumulation of advanced glycation products, which can affect the integration of traditional tissue engineering scaffolds with native bone. Therefore, novel approaches are needed to improve the efficacy of diabetic bone regeneration. This study presents a proof-of-concept development of a multifunctional polymer composite coating tailored towards restoring diabetes-related damage in osteoblast differentiation. Our composite system involves 3D-printed poly(caprolactone fumarate) (PCLF) and poly(caprolactone) (PCL) blend scaffolds coated with multifunctional chitosan methacrylate (chiMA). The chiMA coating is embedded with a sustained-release formulation of glucose oxidase (GOx) from MIL-127 metal-organic frameworks making the coating a stimuli-responsive biomolecule delivery system. The multifunctional coating is designed for the sustained release of GOx and sodium pyruvate for in vitro glucose modulation and oxidative stress reduction, respectively. We propose that sustained release of GOx from MIL-127 embedded chiMA coatings can modulate the high glucose (HG) cellular milieu towards normal glucose (NG), enhancing osteoblast (OB) differentiation via downstream effects. Our results show successful synthesis of MIL-127, encapsulation of GOx, and fabrication of composite coating on the PCLF/PCL scaffolds with effective enzyme activity measured as a function of lowering glucose concentration in HG media for 144 h to normal levels. In vitro evaluation of OB viability, attachment, proliferation, and differentiation showed an overall decrease in cellular activity in HG conditions, which was restored through the glucose-modulating functionality of the GOx-releasing MIL-127 coatings. Our results also presented preliminary evidence of a statistical correlation between DM-related gene markers and osteogenic markers in vitro that requires further exploration. Although this proof-of-concept study holds promise for advancing precision biomaterials development for diabetic tissue engineering and meeting the unmet clinical need for effective treatments and warrants future in vivo evaluation of the composite coating and molecular biology understanding of correlations between DM and osteogenic markers.

04 Nov 2024·Journal of Applied Microbiology

Enhanced d-pantothenic acid biosynthesis by plasmid-free Escherichia coli through sodium pyruvate addition combined with glucose and temperature control strategy

Article

Author: Liu, Zhi-Qiang ; Zheng, Yu-Guo ; Peng, Jin-Bang ; Zhou, Hai-Yan ; Yang, Zi-Jian ; Chen, Yi-Hong

AbstractAimsd-pantothenic acid (d-PA) is an important vitamin widely used in the feed, pharmaceutical, and food industries. This study aims to enhance the d-PA production of a recombinant Escherichia coli without plasmid and inducer induction.Methods and resultsThe fermentation medium in shake flask was optimized, resulting in a 39.50% increased d-PA titer (3.32 g l−1). Subsequently, the fed-batch fermentation in a 5-l fermenter was specifically investigated. First, a two-stage temperature control strategy led to a d-PA titer of 52.09 g l−1. Additionally, a two-stage glucose feeding was proposed and d-PA titer was increased to 65.29 g l−1. It was also found that an appropriate amount of sodium pyruvate was beneficial to cell growth and d-PA synthesis. Finally, a two-stage glucose feeding combined with sodium pyruvate addition resulted in a substantially improved d-PA production with a titer of 72.90 g l−1.ConclusionThe d-PA synthesis was significantly improved through the fermentation process established in this work, i.e. sodium pyruvate addition combined with the temperature and glucose control strategy. The results of this study could provide significant reference for the industrial fermentation production of d-PA.

01 Oct 2024·Ecotoxicology and Environmental Safety

The key metabolic signatures and biomarkers of polycyclic aromatic hydrocarbon-induced blood glucose elevation in chinese individuals exposed to diesel engine exhaust

Article

Author: Miao, Ke ; Chen, Yuanyuan ; Duan, Huawei ; Li, Yanting ; Dai, Yufei ; Gu, Wen ; Wang, Yican ; Zheng, Yuxin ; Long, Yuehan ; Liu, Shuai ; Niu, Yong ; Wang, Mengmeng ; Jiao, Bo ; Tang, Song

Due to the complexity of environmental exposure factors and the low levels of exposure in the general population, identifying the key environmental factors associated with diabetes and understanding their potential mechanisms present significant challenges. This study aimed to identify key polycyclic aromatic hydrocarbons (PAHs) contributing to increased fasting blood glucose (FBG) concentrations and to explore their potential metabolic mechanisms. We recruited a highly PAH-exposed diesel engine exhaust testing population and healthy controls. Our findings found a positive association between FBG concentrations and PAH metabolites, identifying 1-OHNa, 2-OHPh, and 9-OHPh as major contributors to the rise in FBG concentrations induced by PAH mixtures. Specifically, each 10 % increase in 1-OHNa, 2-OHPh, and 9-OHPh concentrations led to increases in FBG concentrations of 0.201 %, 0.261 %, and 0.268 %, respectively. Targeted metabolomics analysis revealed significant alterations in metabolic pathways among those exposed to high levels of PAHs, including sirtuin signaling, asparagine metabolism, and proline metabolism pathway. Toxic function analysis highlighted differential metabolites involved in various dysglycemia-related conditions, such as cardiac arrhythmia and renal damage. Mediation analysis revealed that 2-aminooctanoic acid mediated the FBG elevation induced by 2-OHPh, while 2-hydroxyphenylacetic acid and hypoxanthine acted as partial suppressors. Notably, 2-aminooctanoic acid was identified as a crucial intermediary metabolic biomarker, mediating significant portions of the associations between the multiple different structures of OH-PAHs and elevated FBG concentrations, accounting for 16.73 %, 10.84 %, 10.00 %, and 11.90 % of these effects for 1-OHPyr, 2-OHFlu, the sum concentrations of 2- and 9-OHPh, and the sum concentrations of total OH-PAHs, respectively. Overall, our study explored the potential metabolic mechanisms underlying the elevated FBG induced by PAHs and identified 2-aminooctanoic acid as a pivotal metabolic biomarker, presenting a potential target for intervention.

News (Medical) associated with Sodium Pyruvate

16 Feb 2024

·www.sciencedaily.com

Advanced artificial photosynthesis catalyst uses CO2 more efficiently to create biodegradable plastics

A research team that had previously succeeded in synthesizing fumaric acid using bicarbonate and pyruvic acid, and carbon dioxide collected directly from the gas phase as one of the raw materials, has now created a new photosensitizer and developed a new artificial photosynthesis technology, effectively doubling the yield of fumaric acid production compared to the previous method. The results of this research are expected to reduce carbon dioxide emissions and provide an innovative way to produce biodegradable plastics while reusing waste resources. A research team from Osaka Metropolitan University that had previously succeeded in synthesizing fumaric acid using bicarbonate and pyruvic acid, and carbon dioxide collected directly from the gas phase as one of the raw materials, has now created a new photosensitizer and developed a new artificial photosynthesis technology, effectively doubling the yield of fumaric acid production compared to the previous method. The results of this research are expected to reduce carbon dioxide emissions and provide an innovative way to produce biodegradable plastics while reusing waste resources. Amid growing global concern over climate change and plastic pollution, researchers at Osaka Metropolitan University are making great strides in the sustainable production of fumaric acid -- a component of biodegradable plastics such as polybutylene succinate, which is commonly used for food packaging. The researchers have managed to efficiently produce fumaric acid, which is traditionally derived from petroleum, using renewable resources, carbon dioxide, and biomass-derived compounds. In a previous study, a research team led by Professor Yutaka Amao of the Research Center for Artificial Photosynthesis at Osaka Metropolitan University demonstrated the synthesis of fumaric acid from bicarbonate and pyruvic acid, a biomass-derived compound, using solar energy. They also succeeded in producing fumaric acid using carbon dioxide obtained directly from the gas phase as a raw material. However, the yield in the production of fumaric acid remained low. In their latest research, published in Dalton Transactions, the researchers have now developed a new photosensitizer and further advanced an artificial photosynthesis technique that doubles the yield of fumaric acid compared to conventional methods. "This is an extremely important advancement for the complex bio/photocatalyst system. It is a valuable step forward in our quest to synthesize fumaric acid from renewable energy sources with even higher yields, steering us toward a more sustainable future," said Professor Amao.

21 Nov 2023

·www.prnewswire.com

TAE Life Sciences' Research on Boronotyrosine (BTS) Drug Shows Promise in Advancing Cancer-Fighting Potential of BNCT

Journal of Medicinal Chemistry Publishes Study Demonstrating BTS's Advantages in Cancer Care IRVINE, Calif., Nov. 21, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, today announced groundbreaking findings from its recent research, heralding a new chapter in company's pursuit of making Boron Neutron Capture Therapy (BNCT) a viable and globally accepted cancer treatment. The study focused on the development and boron delivery capabilities of Boronotyrosine (BTS), a novel borylated amino acid analogue that will redefine the cancer-fighting potential of BNCT. Published in the Journal of Medicinal Chemistry, this study highlights BTS's potential to improve BNCT, a cutting-edge cancer therapy modality that combines boronated drugs and a particle accelerator-based neutron source to precisely target and kill cancer cells with minimal damage to healthy tissue. This study demonstrates BTS's unparalleled efficiency in delivering boron—a critical element in BNCT—to LAT1-expressing cancer cells, outperforming the only approved drug for BNCT, Boronophenylalanine (BPA), in both in vivo and in vitro models. The findings reveal that BTS exhibits superior characteristics in terms of cellular uptake, demonstrating a 2-fold to 4-fold greater uptake in vitro compared to BPA. Furthermore, boron retention is significantly higher within cancer cells which retain nearly 60% of the ingested boron after 18 hours, whereas less than 20% is retained after 18 hours with BPA. Notably these results also translated to higher boron delivery over longer periods of time in in vivo experiments. Lastly, the tumor-to-blood ratio with BTS was found to be markedly improved, as high as 28 to 1 compared to only 6 to 1 for BPA, showcasing significantly improved performance in targeting tumors while minimizing exposure to healthy tissue. All these key attributes may be instrumental in enhancing the efficacy of BNCT while minimizing damage to healthy tissues. "TAE Life Sciences' commitment to scientific rigor and innovation is evident in this study," said Dr. Kendall Morrison, Chief Scientific Officer at the company. "The publication of our findings in the Journal of Medicinal Chemistry underscores the meticulous research and robust scientific foundation behind BTS's development and testing." This breakthrough study cements TAE Life Sciences' position as a frontrunner in pioneering cancer treatment advancements in the field of radiation oncology. The promising results pave the way for further research and clinical applications, reaffirming the company's dedication to transforming cancer care. For more information, please refer to the study titled "Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Reemerging Boron Neutron Capture Therapy Field," published in the Journal of Medicinal Chemistry, volume 66, issue 19, pages 13,347 – 13,858. For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit . About TAE Life Sciences TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences' Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at . Press Contact: Michael Farino New Era Communications 949-346-1984 TAE@newerapr.com SOURCE TAE Life Sciences

Radiation Therapy

04 Apr 2023

·www.compositesworld.com

Mito Materials provides in-resin graphene additive for composites

Photo Credit: Mito Material Solutions Specialty chemical company, Mito Material Solutions (Indianapolis, Ind., U.S.) announces its first ready-to-pour graphene product with the company’s verified functionalized graphene status, awarded by the Graphene Council (New Bern, N.C., U.S.). In partnership with industrial coatings manufacturer Forrest Technical Coatings (Eugene, Ore., U.S.), Mito has harnessed its patented, verified technology platform for the production of functionalized graphene into ready-to-pour hybrid additives with chemical and physical bonding points. The first two available ready-to-pour products are Mito E-Go Res-1, a laminating epoxy resin, and Mito Tri-Hdnr-1, an epoxy hardener. The ready-made products may be used separately but their formulas are optimized to work together. “The Mito Res-1 and Tri-Hdnr offering is another example of Mito’s commitment to lower barriers to entry for manufacturers who want to see what functionalized graphene can do in their products,” Haley Marie Keith, CEO and co-founder of Mito, says. “I am excited to see what this partnership with Forrest will enable other manufacturers to create. The possibilities with graphene are limitless, but this new product line gives the power of engineering back to the manufacturers to build anything from stronger and lighter boats to snowboards to bikes and more.” Current Mito client, Folsom Skis, first suggested Mito partner with sports industry formulator Forrest Technical Coatings to make E-Go available in the resin to simplify adoption from a production perspective. Armed with that suggestion and the introduction to Forrest, Mito and Forrest teamed up in creating a ready-to-pour resin mix based off Forrest’s most popular SKUs for sports industry companies using compression molding manufacturing techniques for products. E-Go is pre-mixed in an approximate 1-to-1000 ratio to Forrest’s polymer with the goal of simplifying the complexity of process adoption. According to Mito, its products give fiber-reinforced composites and thermoplastics lab-verified improvements in strength, durability, flexibility, functionality and sustainability. As E-Go is a verified functionalized graphene additive, customers have the assurance that E-Go has passed rigorous audits and third-party testing to ensure product consistency and quality at commercial scale.

100 Deals associated with Sodium Pyruvate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sodium Pyruvate	-	DB00119

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Fibrosis	NDA/BLA	US	EmphyCorp Inc.	12 Aug 2022
Cough	Phase 3	US	Mikra, Cellular Sciences, Inc.Startup	15 Aug 2023
Idiopathic Pulmonary Fibrosis	Phase 3	US	Mikra, Cellular Sciences, Inc.Startup	15 Aug 2023
Cystic Fibrosis	Phase 2	US	EmphyCorp Inc.	12 Aug 2022
Influenza B virus infection	Phase 2	US	EmphyCorp Inc.	12 Aug 2022
Pulmonary Disease, Chronic Obstructive	Phase 1	US	EmphyCorp Inc.	01 Sep 2004
COVID-19	Discovery	US	Mikra, Cellular Sciences, Inc.Startup	12 Apr 2021
COVID-19	Discovery	US	Cellularline SpA	12 Apr 2021
Influenza, Human	Discovery	US	Cellularline SpA	12 Apr 2021
Asthma	Discovery	US	EmphyCorp Inc.	01 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06037408 (CTgov)	Phase 3	Cough \| Idiopathic Pulmonary Fibrosis	50	20mM sodium pyruvate nasal spray (20mM Sodium Pyruvate Nasal Spray Treatment)	mcsaowvmxa(kacivjhfww) = zaowjncmob zdxlzzujok (oyrfvcfuuc, ccvimqeecz - wbxijautin) View more	-	09 Jul 2024
				Saline Placebo control nasal spray (Saline Placebo Control)	mcsaowvmxa(kacivjhfww) = xsaegisbwh zdxlzzujok (oyrfvcfuuc, fxypjfcpgs - jrvpxluwfp) View more
NCT04824365 (CTgov)	Phase 2/3	COVID-19	30	Sodium Pyruvate (Treatment of COVID-19 Infected Patients With a Sodium Pyruvate Nasal Spray)	tlzbfmgykx(ufqzbfkobv) = jjsplstshu mbxpysntdf (rebmltbiji, ovydkascqa - daqbqnxewe) View more	-	26 Sep 2022
				Saline (Placebo Control Treatment of COVID-19 Infected Patients)	tlzbfmgykx(ufqzbfkobv) = mowjbqybgz mbxpysntdf (rebmltbiji, jkuvtjvuwr - barpibvifs) View more
NCT02913131 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm \| Prostatic Cancer	23	MRI+Pyruvate (13C) (Part A: Feasibility Run-In)	ahtvoqahcd(uiomifdgge) = mgwyambyfx btbkqcsmsr (kdalmqaeat, wfsufjmzdb - aeitaepxzw) View more	-	22 Apr 2022
				MRI+Pyruvate (13C) (Part B: Biomarker Cohort)	ahtvoqahcd(uiomifdgge) = pfosvusgah btbkqcsmsr (kdalmqaeat, wiywvkqffk - sbrzjvjzva) View more
ARVO2018	Not Applicable	-	-	Pyruvate 1mM	upfydbwpic(xqmtyodvzu) = xhnvltoauq qqbaszmhqa (hkhkyqqler )	-	01 Jul 2018
				Pyruvate	upfydbwpic(xqmtyodvzu) = catiqxxlqv qqbaszmhqa (hkhkyqqler )
ARVO2013	Not Applicable	stress oxidative	-	Pyruvate	ofurzqbloo(joqghsezkp) = ayginvmekp mkfuvrzorb (qzbqahpgac ) View more	-	01 Jun 2013
NCT00604331 (Pubmed \| Clin Res Cardiol)	Phase 2	Shock, Cardiogenic	8	Intracoronary pyruvate	(nbzmebhfva) = omlleobxig vqioegmasa (wndagvgtbn ) View more	-	01 May 2011
				pyruvate (Catecholamines and intra-aortic balloon pump)	(nbzmebhfva) = ghtrjouwjn vqioegmasa (wndagvgtbn ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis